University of Michigan Board of Regents, Ann Arbor, has approved four investment for its Michigan Investment in New Technology Startups, a venture capital fund co-managed by the university’s investment office and its Office of Technology Transfer.

Attercor, a therapy company for adrenal disorders, CytoPherx, a manufacturer of medical devices to treat inflammation-based diseases using a cytopheresis system, NanoBio Corp., which focuses on developing products to prevent and treat infectious diseases using nanoemulsion droplets and Tissue Regenerative Systems a bioresorbable implants for skeletal reconstruction applications in development, could all receive funding of up to $2.5m each, the university said if the fund’s managers approve the deals.

In December, Regents approved creating the fund, which will invest up to $25 million from the $7.7 billion long-term endowment fund over 10 years in companies using intellectual property licensed through the Office of Technology Transfer.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?